The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...

A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that ...

The results position Belite, one of the sector’s top-performing companies since 2022, to seek approval of what could be the ...

Indiana shows high potential for the state to become the premiere destination to research, commercialize, scale biotechnology ...

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends ...